Artificial Intelligence can predict disease progression. Here is the words of BeCare Link’s CEO in May 2019 of what the future holds for the BeCare Link apps. To watch the video, click the button below.
BeCare Link is an artificial intelligence digital therapeutic company. We’re focused on multiple sclerosis and fall risk to start with.
Size of MS Population
Multiple sclerosis is not really an orphan disease, but it’s not really a blockbuster disease where millions and millions and millions of people have it. A lot of it is a little bit undiagnosed. So the literature says there’s about a million MS patients in the country, about 2.5 million in the world. But I just heard from a neurologist from Houston two weeks ago at a conference who said there’s almost 3 million patients and many of them are undiagnosed.
Tools to Predict Disease Progression
So it’s a real population that is growing. And if we’re able to find tools to be able to find some of those people with certain tools and then to be able to predict their disease progression, because if you can actually do that and look how they’re doing, you can actually bend the cost curve, all the things that we’re trying to do. Betterment for patients, lower hospitalizations, lower flare-up of their multiple sclerosis symptoms. All very, very good things.
Disease Conditions that BeCare Link Will Address
We’re going to start with multiple sclerosis and then start with falls risk components. And our concept is to replicate the gold standard testing methodology for a lot of these conditions. So in multiple sclerosis, that’s called the EDSS and the MS Functional Composite and in falls risk it’s called the Berg Balance. So we see ourselves being able to take those gold standard test methodologies and expanding it to other conditions.
We believe we’re going to stay within the neurological family as we mentioned, Alzheimer’s, stroke, dementia, Parkinson’s, and not go to things like COPD, CHF because we want to really stay in our swim lane, which is a neurological swim lane. That’s a very large area of some of those conditions, where we can take what we’ve learned in multiple sclerosis and apply those to other conditions that have very similar neurological and physical impairment.